Immatics (IMTX) Minority Interest (2019 - 2020)
Immatics (IMTX) posted Minority Interest of $559541.7 for Q2 2020, down 50.44% sequentially from $1.1 million in Q4 2019.
Powered by 
Analysis
Immatics (IMTX) Minority Interest (2019 - 2020) Analysis & Trends
Immatics has reported Minority Interest for 2 years, with the latest figure at $559541.7 in Q2 2020.
- Quarterly Minority Interest changed N/A year-over-year to $559541.7 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $559541.7 (changed N/A YoY) and the FY2019 annual result came in at $1.1 million, changed N/A from the prior year.
- Minority Interest eased to $559541.7 in Q2 2020 per IMTX's latest filing, from $1.1 million in the prior quarter.
- Over five years, Minority Interest peaked at $1.1 million in Q4 2019 and troughed at $559541.7 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |